Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II st... oleh Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, Patrick Schöffski, Yann Godbert, Patrice Rodien, Barbara Jarzab, Domenico Salvatore, Sylvie Zanetta, Jaume Capdevila, Lars Bastholt, Christelle De La Fouchardiere, Yassine Lalami, Stéphane Bardet, Frank Cornélis, Marek Dedecjus, Thera Links, Ward Sents, Martin Schlumberger, D. Laura Locati, Katie Newbold